a Cochrane South Africa, South African Medical Research Council , Cape Town , South Africa.
b European and Developing Countries Clinical Trials Partnership (EDCTP) , Cape Town , South Africa.
Expert Rev Vaccines. 2019 Aug;18(8):859-865. doi: 10.1080/14760584.2019.1640119. Epub 2019 Jul 18.
: Influenza is a highly contagious disease that affects the upper and lower respiratory tract caused by several subtypes of influenza viruses. While vaccination remains the mainstay strategy to protect populations against influenza, there is a global shortage and inequitable access to influenza vaccines. Although influenza vaccine production capacity increased from 500 million doses in 2006 to 1.5 billion doses in 2013, little is known about the global distribution of these vaccines albeit its introduction. We assessed the global status of influenza vaccine introduction. : We analyzed data from the World Health Organization (WHO) Joint Reporting Form, a publicly available source of immunization data from 194 countries of all six WHO regions. We used 2017 data, available as of July 2018. : By December 2017, 117 of 194 (60%) WHO Member States had introduced the seasonal influenza vaccine. European and American regions accounted for 70% (82/117) of the total number of countries that had introduced influenza vaccine. The other four regions account for only 30%. Ninety-four percent (50/53) of countries in the European region and 91% (32/35) in the American region had introduced influenza vaccine. In the Eastern Mediterranean and Western Pacific regions, 67% (14/21) and 52% (14/27), respectively, had introduced the vaccine. Yet only 27% (3/11) and 9% (4/47) in the Southeast Asian and African regions, respectively, had introduced the vaccine. Among countries ( = 117) that had introduced the vaccine, children (56%), older adults (87%), and risk groups (99%) were prioritized and given the vaccines. : Introduction of influenza vaccine in the African and Southeast Asian regions remains suboptimal. This critically underscores the need for financing mechanisms and having countries in the regions that are lagging behind to prioritize seasonal influenza vaccine.
流感是一种由几种流感病毒引起的高度传染性疾病,影响上呼吸道和下呼吸道。虽然疫苗接种仍然是保护人群免受流感影响的主要策略,但流感疫苗全球短缺且获取不平等。尽管流感疫苗已经推出,但人们对其在全球的分布情况知之甚少。我们评估了流感疫苗引入的全球状况。
我们分析了来自世界卫生组织(WHO)联合报告表的数据,这是一个来自所有六个世卫组织区域的 194 个国家的免疫数据公开来源。我们使用了 2017 年的数据,截至 2018 年 7 月可用。
到 2017 年 12 月,194 个世卫组织成员国中的 117 个(60%)已经引入了季节性流感疫苗。欧洲和美洲地区占已引入流感疫苗的国家总数的 70%(82/117)。其他四个地区仅占 30%。欧洲地区的 94%(50/53)和美洲地区的 91%(32/35)的国家已经引入了流感疫苗。在东地中海和西太平洋地区,分别有 67%(14/21)和 52%(14/27)的国家引入了疫苗。然而,在东南亚和非洲地区,分别只有 27%(3/11)和 9%(4/47)的国家引入了疫苗。在已经引入疫苗的国家(= 117 个)中,儿童(56%)、老年人(87%)和高危人群(99%)被优先接种疫苗。
流感疫苗在非洲和东南亚地区的引入仍然不理想。这突出表明需要建立融资机制,并促使该地区落后的国家将季节性流感疫苗作为优先事项。